PDGFA (Platelet Derived Growth Factor Subunit A)

This study provides and defines the first systematic snRNA-seq profiles under OXJF-treated HACE mice. The potential mechanisms of OXJF in treating HACE were related to maintaining energy metabolism, inflammation and BBB homeostasis.

We knocked down THBS1 in rat (BRL, BRL-3A) and human (THLE-2) hepatocytes using siRNA and applied Ruxolitinib to inhibit the JAK2/STAT3 pathway, further clarifying the role of THBS1 in this signaling process...In addition, plasma ELISA revealed that the concentration of THBS1 in plasma increased with increasing radiation dose and degree of RILI, which was consistent with the expression level in the liver tissue. This study provides new insights into the pathogenesis of RILI, and identifies THBS1 as a potential biomarker for RILI diagnosis and monitoring.

Additionally, the transcription factor myocyte enhancer factor 2 C (MEF2C) was found to bind to the promoters of PDGFA, PDGFB, ANGPT1, and ANGPT2, initiating their transcription. Knockdown of MEF2C inhibited the pro-angiogenic activity of MCAM+ myCAFs both in vitro and in vivo MCAM+ myCAFs promote the transcription of pro-angiogenic factors through MEF2C, thereby enhancing angiogenesis and promoting tumor growth in solid-type ACC.

Accumulated IGF2BP2 stabilizes PDGFA mRNA, activating myofibroblastic cancer-associated fibroblasts (myCAFs) through PDGFR interaction, which promotes resistance to gemcitabine. These findings uncover the USP7/IGF2BP2/PDGFA axis as a critical regulatory pathway in PDAC progression and chemoresistance.

These findings suggest that FAM111B mutations drive fibrosis through dysregulated gene networks, highlighting potential therapeutic targets for POIKTMP and related fibrotic diseases. Further research is required to understand FAM111B's role in fibrosis fully.

These novel data strongly suggest a role of these cytokines as potential fibrosis drivers in ALL. More broadly, our findings demonstrate that combined RNA and surface marker analysis is a powerful tool to provide new and valuable insights into bone marrow pathophysiology.

After the docking analysis, the best binding scores are found to be -10.1 kcal/mol for 3a-5GRN, -9.7 kcal/mol for 3b-5GRN, -10.3 kcal/mol for 3c-5GRN, -10.0 kcal/mol for 3d-5GRN, -10.4 kcal/mol for 3e-5GRN and -10.1 kcal/mol for control drug sunitinib-5GRN docked complexes, respectively. The molecular dynamics (MD) simulation incorporating 3c and sunitinib in association with PDGFA (PDB ID: 5GRN) elucidated the potential effectiveness of these compounds.

In addition, NR3C1 negatively correlated with CD4 memory resting T cells, as well as positively correlated with T cells gamma delta (P < 0.05). Our study findings suggested that NR3C1 may serve as an immune-related diagnostic biomarker for BOTs, offering a novel perspective for investigating the development and diagnosis of BOTs.

These findings suggest that, unlike inflammatory fibroid polyps occurring in the gastrointestinal tract, the pathogenesis of nasal polyps occurring in CRS does not involve PDGFRA mutations.

The dysregulated SE landscape of HCC promoted the malignancy phenotype by the upregulation of oncogenes, and SE-regulatory network might be potential drug targets for HCC treatment. Our study deepened the insight of epigenetic dysregulation in HCC, offering the groundwork for SEs as potential therapeutic targets of HCC treatment.

AL patients' sera reflected systemic disturbances affecting MSC growth. So far, decreases in PDGFs, albumin and calcium concentration, as well as platelet count, are the parameters that might be among the causes of this observation.

Notably, four proteins including plasminogen activator urokinase (PLAU), platelet-derived growth factor subunit A (PDGFA), matrix metalloproteinase 3 (MMP3), and neuroblastoma RAS viral oncogene homolog (NRAS) were identified within the prostate cancer pathway, highlighting their potential as biomarkers for the early diagnosis and prognosis of prostate cancer. In conclusion, this study introduced EVlent as a robust platform for the efficient isolation and proteomics analysis of EVs, providing valuable insight into urinary EV biomarkers and their clinical prostate-cancer applications.